SGRY vs DBVT vs ALKS vs USPH

For growth investors, U.

S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Surgery Partners, Inc. (SGRY) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, U. S. Physical Therapy, Inc. is actually cheaper at 20. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: USPH returned +22. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), U.

S. Physical Therapy, Inc. (USPH) is the lower-risk stock at 0. 93β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 35% more volatile than USPH relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 114% for Surgery Partners, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), U.

S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, U.

S. Physical Therapy, Inc. (USPH) trades at 20. 6x forward P/E versus 38. 0x for Surgery Partners, Inc. — 17. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, USPH (3.

1% yield) pays a dividend. SGRY, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, U.

S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). Both have compounded well over 10 years (USPH: +22. 6%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SGRY is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; USPH is a small-cap high-growth stock. USPH pays a dividend while SGRY, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.